TY - JOUR
T1 - Tissue-engineered vascular autograft
T2 - Inferior vena cava replacement in a dog model
AU - Watanabe, M.
AU - Shin'oka, T.
AU - Tohyama, S.
AU - Hibino, Narutoshi
AU - Konuma, T.
AU - Matsumura, G.
AU - Kosaka, Y.
AU - Ishida, T.
AU - Imai, Y.
AU - Yamakawa, M.
AU - Ikada, Y.
AU - Morita, S.
PY - 2001
Y1 - 2001
N2 - Tissue-engineered vascular autografts (TEVAs) were made by seeding 4-6 × 106 of mixed cells obtained from femoral veins of mongrel dogs onto tube-shaped biodegradable polymer scaffolds composed of a polyglycolid acid (PGA) nonwoven fabric sheet and a copolymer of L-lactide and caprolactone (n = 4). After 7 days, the inferior vena cavas (IVCs) of the same dogs were replaced with TEVAs. After 3, 4, 5, and 6 months, angiographies were performed, and the dogs were sacrificed. The implanted TEVAs were examined both grossly and immunohistologically. The implanted TEVAs showed no evidence of stenosis or dilatation. No thrombus was found inside the TEVAs, even without any anticoagulation therapy. Remnants of the polymer scaffolds were not observed in all specimens, and the overall gross appearance similar to that of native IVCs. Immunohistological staining revealed the presence of factor VIII positive nucleated cells at the luminal surface of the TEVAs. In addition, lesions were observed where α-smooth muscle actin and desmin positive cells existed. Implanted TEVAs contained a sufficient amount of extracellular matrix, and showed neither occlusion nor aneurysmal formation. In addition, endothelial cells were found to line the luminal surface of each TEVA. These results strongly suggest that "ideal" venous grafts with antithrombogenicity can be produced.
AB - Tissue-engineered vascular autografts (TEVAs) were made by seeding 4-6 × 106 of mixed cells obtained from femoral veins of mongrel dogs onto tube-shaped biodegradable polymer scaffolds composed of a polyglycolid acid (PGA) nonwoven fabric sheet and a copolymer of L-lactide and caprolactone (n = 4). After 7 days, the inferior vena cavas (IVCs) of the same dogs were replaced with TEVAs. After 3, 4, 5, and 6 months, angiographies were performed, and the dogs were sacrificed. The implanted TEVAs were examined both grossly and immunohistologically. The implanted TEVAs showed no evidence of stenosis or dilatation. No thrombus was found inside the TEVAs, even without any anticoagulation therapy. Remnants of the polymer scaffolds were not observed in all specimens, and the overall gross appearance similar to that of native IVCs. Immunohistological staining revealed the presence of factor VIII positive nucleated cells at the luminal surface of the TEVAs. In addition, lesions were observed where α-smooth muscle actin and desmin positive cells existed. Implanted TEVAs contained a sufficient amount of extracellular matrix, and showed neither occlusion nor aneurysmal formation. In addition, endothelial cells were found to line the luminal surface of each TEVA. These results strongly suggest that "ideal" venous grafts with antithrombogenicity can be produced.
UR - http://www.scopus.com/inward/record.url?scp=0034896859&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034896859&partnerID=8YFLogxK
U2 - 10.1089/10763270152436481
DO - 10.1089/10763270152436481
M3 - Article
C2 - 11506732
AN - SCOPUS:0034896859
SN - 1076-3279
VL - 7
SP - 429
EP - 439
JO - Tissue Engineering
JF - Tissue Engineering
IS - 4
ER -